Page 17 - ESHRE2019
P. 17
Pretreatment AMH predicts long-term ovarian function in early breast cancer
4.0 3.0 2.0 1.0 0.0
CRA
AMH
*
Menses
AMH at diagnosis of early breast cancer is higher in those women who will still be having menses 5 years later
AMH Age
sensitivity 98.2% specificity 80.0% for correct classification of amenorrhoea
n=75
Anderson and Cameron 2011 JCE&M 96, 1336 Anderson et al 2013 Eur J Cancer
Prediction of 70 60
amen 50 40 30 20 10 0
AMH AUC 0.91 (0.870-1.01)
0 20 40 60 80 100
100 90 80
MRC Centre for Reproductive Health at the University of Edinburgh
Ovarian function after Hodgkin lymphoma: A(B)VD vs BEACOPP
100 10 1 0.1 0.01
MRC Centre for Reproductive Health at the University of Edinburgh
Blue: ABVD
Red: BEACOPP
(after 2 cycles of ABVD)
12
Anderson RA et al 2018 Lancet Oncol
PRECONGRESS COURSE 05 I VIENNA, AUSTRIA – 23 JUNE 2019 15
AMH (pmol/L)
Pretreatment
2 cycles
End of treatment
1 yr
2 yr
3 yr
